NCT03694249View on ClinicalTrials.gov

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2026

Conditions
Malignant Solid Tumor
Interventions
DRUG

Ifetroban Sodium

Given by mouth

OTHER

Placebo

Given by mouth

Trial Locations (1)

37232

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors
All Listed Sponsors
collaborator

Cumberland Pharmaceuticals

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER